Table of Contents
<< Previous Issue | Mar 2017 (Vol: 2017, Issue: 3) | Next Issue >> |
- Section: Licensing
-
Immunomedics and Seattle Genetics enter into US$2 B Deal for Sacituzumab Govitecan
-
Allergan Partners with Assembly Bio to Gain Microbiome Gastrointestinal Development Programmes
-
Astellas Advances its Vaccine Ambitions with Affinivax’s Pneumococcal Candidate
-
Akebia Broadens its Pipeline by Licensing J&J’s HIF-Based Portfolio
- Section: Mergers & Acquisitions
-
Vertex Protects Cystic Fibrosis Franchise by Acquiring CTP-656 from Concert
- Section: Opinion & Analysis
-
IMS PharmaDeals: Review of 2016